KNSA Q1 2025 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$138M+72.5% YoY

Gross Profit

$76M55.3% margin

Operating Income

$13M9.6% margin

Net Income

$9M6.2% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

+12.4%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$22M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$599M

Total Liabilities

$142M

Stockholders' Equity

$457M

Cash & Equivalents

$157M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$138M	$80M	+72.5%
Gross Profit	$76M	$48M	+57.5%
Operating Income	$13M	-$17M	+180.2%
Net Income	$9M	-$18M	+148.2%

Revenue Segments

Product

$138M100%